Combined Therapy of Experimental Autoimmune Uveitis by a Dual-Drug Nanocomposite Formulation with Berberine and Dexamethasone

References

• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:10.1080/09273948.2016.1196713
   PubMed Web of Science ®Google Scholar
• Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev. 2014;13(4–5):591–594. doi:10.1016/j.autrev.2014.01.006
   PubMed Web of Science ®Google Scholar
• Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med Prc. 2021;8:695904. doi:10.3389/fmed.2021.695904
   PubMed Web of Science ®Google Scholar
• Li H, Zhang Z, Li Y, et al. Therapeutic effect of rapamycin-loaded small extracellular vesicles derived from mesenchymal stem cells on experimental autoimmune uveitis. Front Immunol. 2022;13:864956. doi:10.3389/fimmu.2022.864956
   PubMed Web of Science ®Google Scholar
• Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm. 2017;25(6):834–840. doi:10.1080/09273948.2016.1184284
   PubMed Web of Science ®Google Scholar
• Ehteshamfar SM, Akhbari M, Afshari JT, et al. Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. J Cell Mol Med. 2020;24(23):3573–3588. doi:10.1111/jcmm.16049
   Web of Science ®Google Scholar
• Jin J, Xu M, Liu Y, et al. Alginate-based composite microspheres coated by berberine simultaneously improve hemostatic and antibacterial efficacy. Colloids Surf B. 2020;194:111168. doi:10.1016/j.colsurfb.2020.111168
   PubMed Web of Science ®Google Scholar
• Lin J, Cai Q, Liang B, et al. Berberine, a traditional Chinese medicine, reduces inflammation in adipose tissue, polarizes M2 macrophages, and increases energy expenditure in mice fed a high-fat diet. Med Sci Monit. 2019;25:87–97. doi:10.12659/MSM.911849
   PubMed Web of Science ®Google Scholar
• Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370(3):602–624. doi:10.1124/jpet.119.256933
   PubMed Web of Science ®Google Scholar
• Dosmar E, Walsh J, Doyel M, et al. Targeting ocular drug delivery: an examination of local anatomy and current approaches. Bioengineering. 2022;9(1):41. doi:10.3390/bioengineering9010041
   PubMedGoogle Scholar
• Machinaga N, Ashley GW, Reid R, et al. A controlled release system for long-acting intravitreal delivery of small molecules. Transl Vis Sci Technol. 2018;7(4):21. doi:10.1167/tvst.7.4.21
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Urtti A. Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res. 2015;137:111–124. doi:10.1016/j.exer.2015.05.003
   PubMed Web of Science ®Google Scholar
• Zhang J, Jiao J, Niu M, et al. Ten years of knowledge of nano-carrier based drug delivery systems in ophthalmology: current evidence, challenges, and future prospective. Int J Nanomed. 2021;16:6497–6530. doi:10.2147/IJN.S329831
   PubMed Web of Science ®Google Scholar
• Ridha AA, Kashanian S, Azandaryani AH, Rafipour R, Mahdavian E. New folate-modified human serum albumin conjugated to cationic lipid carriers for dual targeting of mitoxantrone against breast cancer. Curr Pharm Biotechno. 2020;21(4):305–315. doi:10.2174/1389201020666191114113022
   PubMed Web of Science ®Google Scholar
• Rezaei S, Kashanian S, Bahrami Y, Cruz LJ, Motiei M. Redox-sensitive and hyaluronic acid-functionalized nanoparticles for improving breast cancer treatment by cytoplasmic 17alpha-methyltestosterone delivery. Molecules. 2020;25(5):1181. doi:10.3390/molecules25051181
   PubMed Web of Science ®Google Scholar
• Gomhor JAH, Kashanian S, Rafipour R, Mahdavian E, Mansouri K. Development and characterization of folic acid-functionalized apoferritin as a delivery vehicle for epirubicin against MCF-7 breast cancer cells. Artif Cells Nanomed Biotechnol. 2018;46(3):847–854. doi:10.1080/21691401.2018.1516671
   PubMedGoogle Scholar
• Hemati Azandaryani A, Kashanian S, Derakhshandeh K. Folate conjugated hybrid nanocarrier for targeted letrozole delivery in breast cancer treatment. Pharmaceut Res. 2017;34(12):2798–2808. doi:10.1007/s11095-017-2260-x
   PubMed Web of Science ®Google Scholar
• Bao Z, Yu A, Shi H, et al. Glycol chitosan/oxidized hyaluronic acid hydrogel film for topical ocular delivery of dexamethasone and levofloxacin. Int J Biol Macromol. 2021;167:659–666. doi:10.1016/j.ijbiomac.2020.11.214
   PubMed Web of Science ®Google Scholar
• Balla A, Ruponen M, Valtari A, et al. Understanding dexamethasone kinetics in the rabbit tear fluid: drug release and clearance from solution, suspension and hydrogel formulations. Eur J Pharm Biopharm. 2022;172:53–60. doi:10.1016/j.ejpb.2022.01.005
   PubMed Web of Science ®Google Scholar
• Di Prima G, Licciardi M, Bongiovi F, Pitarresi G, Giammona G. Inulin-based polymeric micelles functionalized with ocular permeation enhancers: improvement of dexamethasone permeation/penetration through bovine corneas. Pharmaceutics. 2021;13(9):1431. doi:10.3390/pharmaceutics13091431
   PubMed Web of Science ®Google Scholar
• Yavuz B, Pehlivan SB, Vural I, Unlu N. In vitro/in vivo evaluation of dexamethasone-PAMAM dendrimer complexes for retinal drug delivery. J Pharm Sci. 2015;104(11):3814–3823. doi:10.1002/jps.24588
   PubMed Web of Science ®Google Scholar
• Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396(1–2):179–187. doi:10.1016/j.ijpharm.2010.06.015
   PubMed Web of Science ®Google Scholar
• Cai M, Xu Z, Zhou X, et al. Long-acting acid-sensitive ketal-linked dexamethasone microcrystals for treating experimental autoimmune uveitis. APL Bioeng. 2022;6(4):046101. doi:10.1063/5.0118311
   PubMed Web of Science ®Google Scholar
• González-Fernández FM, Delledonne A, Nicoli S, et al. Nanostructured lipid carriers for enhanced transscleral delivery of dexamethasone acetate: development, ex vivo characterization and multiphoton microscopy studies. Pharmaceutics. 2023;15(2):407. doi:10.3390/pharmaceutics15020407
   PubMed Web of Science ®Google Scholar
• Kumari S, Dandamudi M, Rani S, et al. Dexamethasone-loaded nanostructured lipid carriers for the treatment of dry eye disease. Pharmaceutics. 2021;13(6):905. doi:10.3390/pharmaceutics13060905
   PubMed Web of Science ®Google Scholar
• Karti O, Saatci AO. Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes. 2021;12(8):1220–1232. doi:10.4239/wjd.v12.i8.1220
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Sella R, Oray M, Friling R, Umar L, Tugal-Tutkun I, Kramer M. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol. 2015;253(10):1777–1782. doi:10.1007/s00417-015-3124-x
   PubMed Web of Science ®Google Scholar
• Jawed Khan M, Hafeez A, Aftab Siddiqui M. Nanocarrier based delivery of berberine: a critical review on pharmaceutical and preclinical characteristics of the bioactive. Curr Pharm Biotechno. 2023;24(11):1449–1464. doi:10.2174/1389201024666230112141330
   PubMed Web of Science ®Google Scholar
• Lai S, Wei Y, Wu Q, et al. Liposomes for effective drug delivery to the ocular posterior chamber. J Nanobiotechnol. 2019;17(1):64. doi:10.1186/s12951-019-0498-7
   PubMed Web of Science ®Google Scholar
• Liu R, Liu Z, Zhang C, Zhang B. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement on transcorneal permeation. J Pharm Sci. 2011;100(8):3186–3195. doi:10.1002/jps.22540
   PubMed Web of Science ®Google Scholar
• Carucci C, Scalas N, Porcheddu A, Piludu M, Monduzzi M, Salis A. Adsorption and release of sulfamethizole from mesoporous silica nanoparticles functionalised with triethylenetetramine. Int J Mol Sci. 2021;22(14):7665. doi:10.3390/ijms22147665
   PubMed Web of Science ®Google Scholar
• Choi JK, Park JY, Lee S, et al. Greater plasma protein adsorption on mesoporous silica nanoparticles aggravates atopic dermatitis. Int J Nanomed. 2022;17:4599–4617. doi:10.2147/IJN.S383324
   PubMed Web of Science ®Google Scholar
• Sun J, Nie H, Pan P, et al. Combined anti-angiogenic and anti-inflammatory nanoformulation for effective treatment of ocular vascular diseases. Int J Nanomed. 2023;18:437–453. doi:10.2147/IJN.S387428
   PubMed Web of Science ®Google Scholar
• Hu C, Sun J, Zhang Y, et al. Local delivery and sustained-release of nitric oxide donor loaded in mesoporous silica particles for efficient treatment of primary open-angle glaucoma. Adv Healthc Mater. 2018;7(23):e1801047. doi:10.1002/adhm.201801047
   PubMed Web of Science ®Google Scholar
• Croissant JG, Fatieiev Y, Almalik A, Khashab NM. Mesoporous silica and organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applications. Adv Healthc Mater. 2018;7(4):1700831.
   Web of Science ®Google Scholar
• Yue Q, Zhang Y, Jiang Y, et al. Nanoengineering of core-shell magnetic mesoporous microspheres with tunable surface roughness. J Am Chem Soc. 2017;139(13):4954–4961. doi:10.1021/jacs.7b01464
   PubMed Web of Science ®Google Scholar
• Liu X, Fan H, Meng Z, et al. Combined silver sulfadiazine nanosuspension with thermosensitive hydrogel: an effective antibacterial treatment for wound healing in an animal model. Int J Nanomed. 2023;18:679–691. doi:10.2147/IJN.S395004
   PubMedGoogle Scholar
• Lyu N, Zhao Y, Xiang J, et al. Inhibiting corneal neovascularization by sustainably releasing anti-VEGF and anti-inflammation drugs from silica-thermogel nanohybrids. Mat Sci Eng C Mater. 2021;128:112274. doi:10.1016/j.msec.2021.112274
   PubMed Web of Science ®Google Scholar
• Sun J, Lei Y, Dai Z, et al. Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma. ACS Appl Mater Interfaces. 2017;9(9):7990–7999. doi:10.1021/acsami.6b16509
   PubMed Web of Science ®Google Scholar
• Sun J, Liu X, Lei Y, et al. Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery. J Mater Chem B. 2017;5(31):6400–6411. doi:10.1039/C7TB01556A
   PubMed Web of Science ®Google Scholar
• Zhang S, Fang Y, Sun J, Deng Y, Lu Y. Improved treatment on ocular inflammation with rationally designed thermoresponsive nanocomposite formulation. Adv Ther. 2021;4(10):2100088. doi:10.1002/adtp.202100088
   Google Scholar
• Lan H, An P, Liu Q, et al. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. J Ethnopharmacol. 2021;274:114073. doi:10.1016/j.jep.2021.114073
   PubMed Web of Science ®Google Scholar
• Zhao Y, Huang C, Zhang Z, et al. Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma. Drug Deliv. 2022;29(1):613–623. doi:10.1080/10717544.2022.2039806
   PubMed Web of Science ®Google Scholar
• Copland DA, Wertheim MS, Armitage WJ, Nicholson LB, Raveney BJ, Dick AD. The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation. Invest Ophth Vis Sci. 2008;49(12):5458–5465. doi:10.1167/iovs.08-2348
   PubMed Web of Science ®Google Scholar
• Kohno H, Sakai T, Saito S, Okano K, Kitahara K. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin. Exp Eye Res. 2007;84(3):569–576. doi:10.1016/j.exer.2006.11.011
   PubMed Web of Science ®Google Scholar
• Caspi RR, Roberge FG, McAllister CG, et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol. 1986;136(3):928–933. doi:10.4049/jimmunol.136.3.928
   PubMed Web of Science ®Google Scholar
• Bhatnagar P, Kumari M, Pahuja R, et al. Hyaluronic acid-grafted PLGA nanoparticles for the sustained delivery of berberine chloride for an efficient suppression of Ehrlich ascites tumors. Drug Deliv Transl Re. 2018;8(3):565–579. doi:10.1007/s13346-018-0485-9
   PubMed Web of Science ®Google Scholar
• Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2021;80:100866. doi:10.1016/j.preteyeres.2020.100866
   PubMed Web of Science ®Google Scholar
• Weinstein JE, Pepple KL. Cytokines in uveitis. Curr Opin Ophthalmol. 2018;29(3):267–274. doi:10.1097/ICU.0000000000000466
   PubMed Web of Science ®Google Scholar
• Nehme A, Edelman J. Dexamethasone inhibits high glucose–, TNF-α–, and IL-1β–induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophth Vis Sci. 2008;49(5):2030–2038. doi:10.1167/iovs.07-0273
   PubMed Web of Science ®Google Scholar
• Yang P. Editorial: uveitis: pathology, molecular mechanisms and therapy. Curr Mol Med. 2018;17(7):459. doi:10.2174/1566524018666180207161909
   PubMed Web of Science ®Google Scholar
• Fang CB, Zhou DX, Zhan SX, et al. Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. PLoS One. 2013;8(4):e62071. doi:10.1371/journal.pone.0062071
   PubMed Web of Science ®Google Scholar
• Luo L, Yang J, Oh Y, et al. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. J Controlled Release. 2019;296:68–80. doi:10.1016/j.jconrel.2019.01.018
   PubMed Web of Science ®Google Scholar
• Singh RB, Sinha S, Saini C, Elbasiony E, Thakur S, Agarwal A. Recent advances in the management of non-infectious posterior uveitis. Int Ophthalmol. 2020;40(11):3187–3207. doi:10.1007/s10792-020-01496-0
   PubMed Web of Science ®Google Scholar
• Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40(1):38–49. doi:10.1016/j.tips.2018.11.002
   PubMed Web of Science ®Google Scholar
• Stimpson ML, Lait PJP, Schewitz-Bowers LP, et al. IL-10 and IL-17 expression by CD4(+) T cells is altered in corticosteroid refractory immune thrombocytopenia (ITP). J Thromb Haemost. 2020;18(10):2712–2720. doi:10.1111/jth.14970
   PubMed Web of Science ®Google Scholar
• Tillhon M, Guaman Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012;84(10):1260–1267. doi:10.1016/j.bcp.2012.07.018
   PubMed Web of Science ®Google Scholar
• Li YH, Xiao HT, Hu DD, et al. Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. Pharmacol Res. 2016;110:227–239. doi:10.1016/j.phrs.2016.02.010
   PubMed Web of Science ®Google Scholar
• Jia X, Jia L, Mo L, et al. Berberine ameliorates periodontal bone loss by regulating gut microbiota. J Dent Res. 2019;98(1):107–116. doi:10.1177/0022034518797275
   PubMed Web of Science ®Google Scholar
• Song H, Ahmad Nor Y, Yu M, et al. Silica nanopollens enhance adhesion for long-term bacterial inhibition. J Am Chem Soc. 2016;138(20):6455–6462. doi:10.1021/jacs.6b00243
   PubMed Web of Science ®Google Scholar
• Yang K, Wen J, Liu X, et al. Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-gamma in Vogt-Koyanagi-Harada patients. Brit J Ophthalmol. 2009;93(2):249–253. doi:10.1136/bjo.2008.142489
   PubMed Web of Science ®Google Scholar